Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumour induced hypercalcaemia: a case for active treatment

N P O'Rourke1, E V McCloskey, J A Kanis

  • 1Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1994
PubMed
Summary

Tumor-induced hypercalcemia is often missed or undertreated in cancer patients. Prompt bisphosphonate treatment effectively lowers serum calcium, improving patient symptoms despite poor prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of FRAXplus adjustments on fracture risk reclassification in older Swedish women-results from the SUPERB-study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

A surrogate FRAX model for Mongolia.

Archives of osteoporosis·2025
Same author

Conflating the Operational Definition of Osteoporosis with Intervention Thresholds.

Calcified tissue international·2025
Same author

A surrogate FRAX model for Nepal.

Archives of osteoporosis·2024
Same author

An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.

Journal of endocrinological investigation·2023
Same author

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023

Area of Science:

  • Oncology
  • Endocrinology
  • Clinical Medicine

Background:

  • Hypercalcemia is a common complication in cancer patients.
  • Tumor-induced hypercalcemia significantly impacts patient prognosis and quality of life.

Purpose of the Study:

  • To retrospectively analyze the diagnosis, management, and outcomes of hypercalcemia in a regional oncology center.
  • To evaluate the effectiveness of bisphosphonate therapy in managing tumor-induced hypercalcemia.

Main Methods:

  • Retrospective survey of 168 patients with tumor-induced hypercalcemia over 12 months.
  • Analysis of case records to assess diagnosis and treatment patterns.
  • Evaluation of treatment outcomes, including serum calcium levels and survival.

Related Experiment Videos

Main Results:

  • Hypercalcemia was underdiagnosed or untreated in 50% of patients.
  • Bisphosphonates were administered to 38% of patients, with 71% receiving them for serum calcium > 3 mmol/l.
  • Bisphosphonate treatment led to a serum calcium decrease in 98% of patients within a week.
  • Median survival from hypercalcemia onset was 2 months.

Conclusions:

  • A significant proportion of tumor-induced hypercalcemia cases are missed or inadequately managed.
  • Active management, particularly with bisphosphonates, is warranted for symptomatic relief, even with a poor prognosis.
  • Further attention is needed to improve the diagnosis and treatment of hypercalcemia in oncology settings.